
Siamak Daneshmand MD
Minimally Invasive Surgery, Surgical Oncology
Professor of Urology (Clinical Scholar); Director of Urologic Oncology
Join to View Full Profile
1516 San Pablo StFl 5Los Angeles, CA 90033
Phone+1 323-865-3700
Fax+1 323-865-0120
Dr. Daneshmand is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- BIOGRAPHY
Dr. Sia Daneshmand is Professor of Urology and Medicine (Oncology) with Clinical Scholar designation and serves as director of urologic oncology, as well as the urologic oncology (SUO) fellowship director at the University of Southern California in Los Angeles. His main clinical interests include bladder, testicular, and advanced kidney cancers. He is a leading authority in the management of complex germ cell tumors and nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testicular cancer and is one of the highest volume surgeons for this disease in the country. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy and post-chemo RPLND, use of serum and molecular markers and new technologies in diagnosis and management of bladder and testicular cancers, as well as functional outcomes following orthotopic urinary diversion. He serves on the AUA Guidelines panel for non-muscle invasive bladder cancer, as well as the AUA Guidelines panel for Testicular cancer. He currently serves as the chair of bladder section of the SUO Clinical Trials Consortium (SUO-CTC), is on the scientific steering committee of several bladder cancer clinical trials and has led over a dozen clinical trials in bladder cancer and a pivotal investigator initiated mutli-institutional trial in testicular cancer (SEMS). He is current secretary of the Western Section of the AUA. He is a member of Alpha Omega Alpha medical honor society and has been designated one of the “America’s Top Cancer Doctors” for the past 13 consecutive years. He has been a career leader in academic investigations in bladder and germ cell cancers and was recently appointed as the chair of the SWOG local bladder committee. He has been a visiting professor at 26 institutions worldwide. He has presented over 500 abstracts authored or co-authored over 400 peer-reviewed articles, reviews, and book chapters.
Education & Training
- University of Southern California/LAC+USC Medical CenterFellowship, Urologic Surgical Oncology, 2002 - 2004
- University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Urology, 1996 - 2002
- University of California, Davis, School of MedicineClass of 1996
- University of California, Los AngelesB.S., Microbiology & Molecular Genetics, Magna Cum Laude, 1988 - 1992
Certifications & Licensure
- OR State Medical License 2004 - Present
- CA State Medical License 1997 - 2027
- American Board of Urology Urology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2017
- America's Top Doctors for Cancer Castle Connolly, 2009-2017
- Winner Best Poster of Session AUA, 2016
- Join now to see all
Clinical Trials
- Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma Start of enrollment: 2004 Nov 01
- S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin Start of enrollment: 2006 Nov 01
- A Comparison of the Studer Pouch Versus the T-Pouch Orthotopic Neobladder Urinary Diversion in Bladder Cancer Patients Start of enrollment: 2002 Jan 04
- Join now to see all
Publications & Presentations
PubMed
- Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.Shilpa Gupta, Patrick J Hensley, Roger Li, Ananya Choudhury, Siamak Daneshmand
European Urology. 2025-04-22 - Accuracy of 18F-FDG PET in Early Metastatic Testicular Seminoma: Analysis from the SEMS Trial.Brian Hu, Muhannad Alsyouf, Ala'a Farkouh, Clint Cary, Timothy Masterson
The Journal of Urology. 2025-04-09 - A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy.Joep J de Jong, James A Proudfoot, Siamak Daneshmand, Robert S Svatek, Vikram Narayan
BJU International. 2025-04-01
Journal Articles
- Frailty as a Predictor of Complications After Radical Cystectomy: A Prospective Study of Various Preoperative AssessmentsMadeleine L Burg, Anne K Schuckman, Hooman Djaladat, Siamak Daneshmand, Urologic Oncology
- Urology Photo Quiz: Adrenal myelolipomaQuek ML and Daneshmand S, Resident & Staff Physician, 1/1/2004
- Placental pathology casebook Complete hydatidiform mole with coexistent term twin pregnancyAlbers E, Daneshmand S, Hull A, J Perinatol, 1/1/2001
Books/Book Chapters
Abstracts/Posters
- Preoperative testosterone levels are associated with testicular germ cell tumor histology.Cory Hugen, Anne Schuckman, Hooman Djaladat, Victoria Cortessis, Siamak Daneshmand, Society of International Urology, Buenos Aires, Argentina, 1/1/2016
- Female cystectomy with orthotopic urinary diversion - is fear of urethral recurrence justified?Cory Hugen, Gus Miranda, Jie Cai, Anne Schuckman, Hooman Djaladat, Sia Daneshmand, Society of International Urology, Buenos Aires, Argentina, 1/1/2016
- Enhanced Recovery After Surgery (ERAS) following Radical Cystectomy and Urinary Diversion.Siamak Daneshmand, Society of International Urology, Buenos Aires, Argentina, 1/1/2016
- Join now to see all
Lectures
- Urinary Diversion Following Radical Cystectomy- Separating Myth from Fact1/1/2016
- AUA Difficult Cases Plenary II Testis Cancer.1/1/2016
- AUA Bladder Cancer Guidelines Update1/1/2016
- Join now to see all
Other
- Lymph node dissection in bladder cancer. (Performed radical cystectomy for bladder cancer.)Daneshmand S, Labbafinejad Urology Department
Shahid Beheshti University of Medical Sciences, Tehran, Iran - 1/1/2014 - Health Heroes- Blue light cystoscopyDaneshmand S, Discovery Health
1/1/2013 - Treatment for Testicular cancer.Daneshmand S, Doctors TV show
http://www.thedoctorstv.com/videolib/init/8028
1/1/2012 - Join now to see all
Authored Content
- Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
- Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
- Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
Press Mentions
- High Response Rate for TAR-200 plus Cetrelimab in BCG-Unresponsive NMIBCMay 24th, 2023
- Novel Chemotherapy Delivery System May Fill Key Gap in Bladder Cancer TreatmentMay 3rd, 2023
- Novel Chemo Delivery System Achieves High Response Rate in Bladder CancerMay 2nd, 2023
- Join now to see all
Professional Memberships
- Member
External Links
- USC Urologyhttp://www.uscurology.com/doctor/bio/view/126223
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: